Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.37 |
| ▸ | SCN4A | P35499 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4606178 | 0.81 | ALDH1A1 (0.57) | SMN1; SMN2RAB9ANPC1MAPTPTGS2 | |
| SCHEMBL4066085 | 0.78 | FYN (0.43) | NR1H2SCN3ASCN4AHSP90AA1HSP90AB1 | |
| SCHEMBL24176881 | 0.77 | SMN1; SMN2 (0.38) | SMN1; SMN2NR1H2SCN3ASCN4ARAB9A | |
| SCHEMBL23213623 | 0.75 | HSP90AA1 (0.41) | SMN1; SMN2NR1H2GPR119SCN3ASCN4A | |
| SCHEMBL29795977 | 0.75 | HSP90AA1 (0.41) | SMN1; SMN2NR1H2GPR119SCN3ASCN4A | |
| SCHEMBL981026 | 0.74 | NR1H2 (0.69) | NR1H2NR1H3 | |
| SCHEMBL24368122 | 0.71 | MAP4K4 (0.41) | NR1H2SCN3ASCN4ARAB9ANPC1 | |
| SCHEMBL3920471 | 0.71 | NPC1 (0.42) | NR1H2GPR119SCN3ASCN4ARAB9A | |
| SCHEMBL21296771 | 0.71 | MAP2K4 (0.39) | SMN1; SMN2NR1H2SCN3ASCN4ARAB9A | |
| SCHEMBL29938346 | 0.71 | SCN9A (0.43) | SMN1; SMN2NR1H2SCN3ASCN4ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | WEIGAND KLAUS | 2008-12-11 | — | — | US | disclosed |
| EP-1943235-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Novartis AG (CH) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007048771-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | CCR3, CCR1, CCR4 | SMN1; SMN2 4305/4885NR1H2 63/4885GPR119 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.